There was no difference in the occurrence of hypoglycemia or DKA after the initiation of GLP-1 RA therapy, even considering that many participants (n = 23 out of 36 participants for which C-peptide values were available; 63.9%) had C-peptide values lower than 0.2 nmol/L. This evidence concerns the gene GLP1R and Hypoglycemia.